BioCentury | Dec 12, 2018
Distillery Therapeutics
Neurology
...disease (AD); frontotemporal dementia; progressive supranuclear palsy (PSP) Patient sample and mouse studies suggest inhibiting LGMN-mediated...
...and PSP. In brain tissue samples from patients with AD, FTD or PSP, levels of LGMN...
...steps could include developing a small molecule that blocks the LGMN-SRPK2 interaction. TARGET/MARKER/PATHWAY: Legumain (LGMN; AEP...
...and PSP. In brain tissue samples from patients with AD, FTD or PSP, levels of LGMN...
...steps could include developing a small molecule that blocks the LGMN-SRPK2 interaction. TARGET/MARKER/PATHWAY: Legumain (LGMN; AEP...